WEST PHARMACEUTICAL SERVICES, INC. (WST) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 640.50M USD | Liabilities, Current |
| Cash and equivalents | 435.80M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 712.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 447.40M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $640.50M | $435.80M | (m) | $712.00M | $447.40M | (m) |
| 2026-03-31 | (m) | $674.00M | $521.40M | (m) | $685.60M | $452.60M | (m) |
| 2025-12-31 | (m) | $654.90M | $791.30M | (m) | $574.40M | $443.90M | (m) |
| 2025-09-30 | (m) | $635.40M | $628.50M | (m) | $625.00M | $438.00M | (m) |
| 2025-06-30 | (m) | $604.60M | $509.70M | (m) | $582.40M | $421.10M | (m) |
| 2025-03-31 | (m) | $526.70M | $404.20M | (m) | $543.60M | $388.70M | (m) |
| 2024-12-31 | (m) | $550.40M | $484.60M | (m) | $552.50M | $377.00M | (m) |
| 2024-09-30 | (m) | $516.50M | $490.90M | (m) | $524.30M | $401.20M | (m) |
| 2024-06-30 | (m) | $633.70M | $446.20M | (m) | $479.40M | $419.20M | (m) |
| 2024-03-31 | (m) | $648.40M | $601.80M | (m) | $524.00M | $429.90M | (m) |
| 2023-12-31 | (m) | $671.80M | $853.90M | (m) | $512.00M | $434.70M | (m) |
| 2023-09-30 | (m) | $533.50M | $898.60M | (m) | $519.10M | $431.80M | (m) |
| 2023-06-30 | (m) | $511.60M | $796.30M | (m) | $534.40M | $449.40M | (m) |
| 2023-03-31 | (m) | $534.90M | $886.30M | (m) | $513.40M | $447.00M | (m) |
| 2022-12-31 | (m) | $519.00M | $894.30M | (m) | $507.40M | $414.80M | (m) |
| 2022-09-30 | (m) | $456.70M | $729.00M | (m) | $485.30M | $413.10M | (m) |
| 2022-06-30 | (m) | $565.10M | $718.50M | (m) | $528.40M | $411.60M | (m) |
| 2022-03-31 | (m) | $584.80M | $667.70M | (m) | $498.70M | $416.50M | (m) |
| 2021-12-31 | (m) | $594.10M | $762.60M | (m) | $489.00M | $378.40M | (m) |
| 2021-09-30 | (m) | $558.60M | $688.00M | (m) | $476.40M | $353.80M | (m) |
| 2021-06-30 | (m) | $472.60M | $576.20M | (m) | $480.50M | $345.20M | (m) |
| 2021-03-31 | (m) | $482.80M | $483.70M | (m) | $465.70M | $310.20M | (m) |
| 2020-12-31 | (m) | $503.40M | $615.50M | (m) | $385.30M | $321.30M | (m) |
| 2020-09-30 | (m) | $447.70M | $519.40M | (m) | $373.00M | $294.90M | (m) |
| 2020-06-30 | (m) | $375.20M | $445.90M | (m) | $340.60M | $274.80M | (m) |
| 2020-03-31 | (m) | $344.40M | $335.30M | (m) | $333.00M | $251.00M | (m) |
| 2019-12-31 | (m) | $341.60M | $439.10M | (m) | $319.30M | $235.70M | (m) |
| 2019-09-30 | (m) | $335.00M | $396.00M | (m) | $316.10M | $230.40M | (m) |
| 2019-06-30 | (m) | $313.20M | $326.70M | (m) | $330.80M | $232.30M | (m) |
| 2019-03-31 | (m) | $301.10M | $265.50M | (m) | $318.20M | $226.10M | (m) |
| 2018-12-31 | (m) | $283.70M | $337.40M | (m) | $288.20M | $214.50M | (m) |
| 2018-09-30 | (m) | $288.80M | $297.30M | (m) | $302.90M | $206.80M | (m) |
| 2018-06-30 | (m) | $287.60M | $225.50M | (m) | $296.70M | $208.20M | (m) |
| 2018-03-31 | (m) | $263.40M | $199.80M | (m) | $290.40M | $215.70M | (m) |
| 2018-01-01 | (m) | (m) | (m) | (m) | $278.20M | $194.40M | (m) |
| 2017-12-31 | (m) | $279.50M | $235.90M | (m) | $253.20M | $215.20M | (m) |
| 2017-09-30 | (m) | $300.00M | $269.30M | (m) | $251.80M | $215.80M | (m) |
| 2017-06-30 | (m) | $289.00M | $226.60M | (m) | $242.40M | $211.30M | (m) |
| 2017-03-31 | (m) | $256.50M | $169.40M | (m) | $224.80M | $212.30M | (m) |
| 2016-12-31 | (m) | $241.00M | $203.00M | (m) | $200.50M | $199.30M | (m) |
| 2016-09-30 | (m) | $236.80M | $205.90M | (m) | $209.50M | $201.10M | (m) |
| 2016-06-30 | (m) | $239.40M | $202.70M | (m) | $219.00M | $197.70M | (m) |
| 2016-03-31 | (m) | $241.10M | $178.10M | (m) | $209.60M | $194.10M | (m) |
| 2015-12-31 | (m) | $314.30M | $274.60M | (m) | $181.40M | $181.10M | (m) |
| 2015-09-30 | (m) | $299.90M | $256.80M | (m) | $194.60M | $187.70M | (m) |
| 2015-06-30 | (m) | $313.70M | $252.00M | (m) | $198.80M | $187.20M | (m) |
| 2015-03-31 | (m) | $296.60M | $207.10M | (m) | $189.50M | $183.40M | (m) |
| 2014-12-31 | (m) | $252.50M | $255.30M | (m) | $179.00M | $181.50M | (m) |
| 2014-09-30 | (m) | $242.50M | $246.80M | (m) | $195.90M | $185.70M | (m) |
| 2014-06-30 | (m) | $221.20M | $226.70M | (m) | $209.60M | $187.90M | (m) |
| 2014-03-31 | (m) | $227.60M | $230.00M | (m) | $208.70M | $187.50M | (m) |
| 2013-12-31 | (m) | $236.90M | $230.00M | (m) | $185.70M | $176.90M | (m) |
| 2013-09-30 | (m) | $246.80M | $221.70M | (m) | $198.20M | $176.70M | (m) |
| 2013-06-30 | (m) | $218.70M | $190.60M | (m) | $195.30M | $176.50M | (m) |
| 2013-03-31 | (m) | $208.10M | $175.00M | (m) | $189.00M | $173.50M | (m) |
| 2012-12-31 | (m) | $261.80M | $161.90M | (m) | $175.00M | $162.20M | (m) |
| 2012-09-30 | (m) | $275.60M | $143.20M | (m) | $182.90M | $165.90M | (m) |
| 2012-06-30 | (m) | $320.20M | $107.00M | (m) | $185.00M | $159.20M | (m) |
| 2012-03-31 | (m) | $302.40M | $100.20M | (m) | $176.00M | $158.20M | (m) |
| 2011-12-31 | (m) | $243.20M | $91.80M | (m) | $147.20M | $151.80M | (m) |
| 2011-09-30 | (m) | $229.30M | $119.20M | (m) | $153.10M | $155.50M | (m) |
| 2011-06-30 | (m) | $192.70M | $110.40M | (m) | $165.70M | $161.20M | (m) |
| 2011-03-31 | (m) | $182.80M | $94.60M | (m) | $161.20M | $157.10M | (m) |
| 2010-12-31 | (m) | $169.70M | $110.20M | (m) | $126.40M | $147.00M | (m) |
| 2010-09-30 | (m) | $158.20M | $97.10M | (m) | $142.80M | $148.40M | (m) |
| 2010-06-30 | (m) | $158.60M | $67.50M | (m) | $145.70M | $143.30M | (m) |
| 2010-03-31 | (m) | (m) | $65.90M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $171.10M | $83.10M | (m) | $138.70M | $129.20M | (m) |
| 2009-09-30 | (m) | (m) | $79.50M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $84.30M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $87.20M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $108.40M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |